Assembly Biosciences
ASMB
65 hedge funds and large institutions have $259M invested in Assembly Biosciences in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 12 closing their positions.
4,736% more call options, than puts
Call options by funds: $4.16M | Put options by funds: $86K
133% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 12
33% more funds holding
Funds holding: 49 → 65 (+16)
0.28% more ownership
Funds ownership: 5.75% → 6.03% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less capital invested
Capital invested by funds: $301M → $259M (-$42.8M)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.81M |
| 3 |
JP Morgan Chase
New York
|
+$3.89M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.16M |
| 5 |
Renaissance Technologies
New York
|
+$3.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$8.66M |
| 2 |
QF
QVT Financial
New York
|
-$7.1M |
| 3 |
PA
Perceptive Advisors
New York
|
-$5.22M |
| 4 |
Millennium Management
New York
|
-$2.54M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$2.09M |
ASMB Hedge Fund Activity: Q2 2017 in Review
65 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q2 2017, worth a combined $259M — down 14% from $301M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ASMB positions and 12 closed out — a net gain of 16 holders — while 14 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $12.9M. The largest seller was OrbiMed, cutting an estimated $8.66M.
- 65 institutional investors held Assembly Biosciences (ASMB) as of Q2 2017, up from 49 in Q1 2017.
- Funds reported $259M of Assembly Biosciences stock for Q2 2017, down 14% quarter-over-quarter.
- 28 funds opened new Assembly Biosciences positions in Q2 2017 and 12 closed out, a net change of +16 holders.
- The largest Assembly Biosciences buyer in Q2 2017 was BlackRock, an estimated $12.9M added.
- The largest Assembly Biosciences seller in Q2 2017 was OrbiMed, an estimated $8.66M sold.
Based on aggregated 13F filings for Q2 2017.